Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02831959 | Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). | PHASE3 | COMPLETED | 298 | — | — | Jul 1, 2016 | Nov 29, 2024 | Oct 31, 2025 | 128 | United States, Austria +13 |
| Arm | Type | Description |
|---|---|---|
| NovoTTF-200M device | EXPERIMENTAL | NovoTTF-200M device Patients undergo SRS followed by continuous TTFields treatment using the NovoTTF-200M device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine. |
| Best Standard of Care | ACTIVE_COMPARATOR | Patients will undergo SRS alone and be treated with the best known standard of care for Non-Small Cell Lung Cancer metastatic to the brain. |
| Name | Type | Description |
|---|---|---|
| NovoTTF-200M device | DEVICE | - |
| Best Standard of Care | OTHER | - |
Inclusion Criteria: 1. 18 years of age and older 2. Life expectancy of ≥ 3 months 3. New diagnosis of brain metastases from a histologically or cytologically confirmed primary or metastatic NSCLC tumor within 5 years of registration on the study. If the original histological proof of malignancy is ...